Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by SouthernTierTomon Nov 15, 2021 11:04pm
131 Views
Post# 34130113

RE:RE:Corporate Update provides new language RE: Tigris efficacy?

RE:RE:Corporate Update provides new language RE: Tigris efficacy?Thanks MM, we appreciate your support of our investment and most importantly the "truth". 

The science is "tight", the ownership "tighter" and the need for the proven science "unquestionable"...the term "unmet need" truly an understatement in the area of Endotoxemic Septic Shock.

I am very pleased to see Dr. John Kellum leave academia to join our team.  Clearly he has been an integral part of the story for many years and his understanding of PMX under the strict guidance of the FDA approved EAA diagnostic has obviously captured his imagination and more importantly his focus.  I find it interesting when KOL's ( Ronco, Vincent, etc.. ) speak of moving beyond "28 day mortality" as a primary endpoint to advance innovation in the area of critical care.  My detailed analysis of the EAA, PMX and the state-of-the-art SAMI hemoperfusion pump leads me to believe we "need not abandon 28 day mortality" in the area of Endotoxemic Septic Shock thanks to Spectral Medical, Toray of Japan and Infomed of Switzerland.  The "theranostic" approach and the innovation of the EAA diagnostic thanks to Dr. Paul Walker and his colleague Dr. Alex Romaschin as it pushes closer and closer to providing an option for those stricken with "Endotoxemic Septic Shock" where no other option exists.  I'm excited for what the TIGERIS will bring and not at all surprised that the story continues to be "escorted" by a rogue group of  Beech Boy naysayers all the way to the finish line.  The end result is potentially game-changing for both EDT and all those that will claim to "sweep away the residual cytokines"  We often hear of "cytokine storms", but the most obvious of "storms" is the 24/7 maintenance program over the last 20 years being run on this public forum....let it continue and let all people be wise enough to understand why ; - )

Bon appy,
Tom


<< Previous
Bullboard Posts
Next >>